Pembrolizumab Prior to Surgery for Stage 1B, 2 or 3A Non-small Cell Lung Cancer (NSCLC): A Phase II Study

Trial Profile

Pembrolizumab Prior to Surgery for Stage 1B, 2 or 3A Non-small Cell Lung Cancer (NSCLC): A Phase II Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms TOP 1501
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 27 Jan 2017 Status changed from not yet recruiting to recruiting.
    • 16 Aug 2016 Planned End Date changed from 1 Nov 2024 to 1 Jan 2027.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top